Skip to main content
Fig. 10 | Journal of Experimental & Clinical Cancer Research

Fig. 10

From: Novel role of miR-133a-3p in repressing gastric cancer growth and metastasis via blocking autophagy-mediated glutaminolysis

Fig. 10

miR-133a-3p blocks GC growth and metastasis better with the combination of autophagy and glutaminolysis inhibitors in vivo. (a). Procedures of establishing PDX model. (b). Clinical characteristics of the donor patients. (c). H&E staining of the donor patients’ tissues, scale bar = 100 μm. (d). Lower weight and volume of the xenografted tumors could be observed under LV-miR-133a-3p treatment compared with the LV-NC and LV-miR-133a-3p-IN groups and the tumor growth was further inhibited under drug-combination groups. (e). We found increased and persistent level of miR-133a-3p in LV-miR-133a-3p treated groups compared with the LV-NC group and a much higher level of miR-133a-3p in the drug-combination groups. (f). We determined the LC3,GLS and GDH levels in the different groups of PDX tumors by immunohistochemistry, scale bar = 100 μm. (g). We determined the role of miR-133a-3p on metastasis in vivo by tail vein injection LV-miR-133a-3p.LV-NC,LV-miR-133a-3p IN GC cells and we than measured the luciferase intensities each week. (h). We took H&E staining to show the lung metastasis foci. (i). The expression level of LC3,P62,GLS,GDH,GABARAPL1, ATG13 and EMT markers in PDX tumors was determined by western blot. All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page